Literature DB >> 18237557

Expression of sulfotransferases involved in the biosynthesis of chondroitin sulfate E in the bone marrow derived mast cells.

Shiori Ohtake1, Sachiko Kondo, Toshiko Morisaki, Kaori Matsumura, Koji Kimata, Osami Habuchi.   

Abstract

Bone marrow-derived mast cells (BMMCs) contain chondroitin sulfate (CS)-E comprised of GlcA-GalNAc(4SO4) units and GlcA-GalNAc(4,6-SO4) units. GalNAc 4-sulfate 6-O-sulfotransferase (GalNAc4S-6ST) transfers sulfate to position 6 of GalNAc(4SO4) residues of CS. On the basis of the specificity of GalNAc4S-6ST, it is thought that CS-E is synthesized in BMMC through the sequential sulfation by chondroitin 4-sulfotransferase (C4ST)-1 and GalNAc4S-6ST. In this paper, we investigated whether GalNAc4S-6ST and C4ST-1 are actually expressed in BMMCs in which CS-E is actively synthesized. As the bone marrow cells differentiate to BMMCs, level of C4ST-1 and GalNAc4S-6ST messages increased, whereas chondroitin 6-sulfotransferase (C6ST)-1 message decreased. In the extract of BMMCs, activity of GalNAc4S-6ST and C4ST but not C6ST were detected. The recombinant mouse GalNAc4S-6ST transferred sulfate to both nonreducing terminal and internal GalNAc(4SO4) residues; the activity toward nonreducing terminal GalNAc(4SO4) was increased with increasing pH. When CS-E synthesized by BMMCs was metabolically labeled with 35SO4 in the presence of bafilomycin A, chloroquine or NH4Cl, the proportion of the nonreducing terminal GalNAc(4,6-SO4) was increased compared with the control, suggesting that GalNAc4S-6ST in BMMC may elaborate CS-E in the intracellular compartment with relatively low pH where sulfation of the internal GalNAc(4SO4) by GalNAc4S-6ST preferentially occurs.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18237557     DOI: 10.1016/j.bbagen.2008.01.004

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  7 in total

1.  Mice deficient in N-acetylgalactosamine 4-sulfate 6-o-sulfotransferase are unable to synthesize chondroitin/dermatan sulfate containing N-acetylgalactosamine 4,6-bissulfate residues and exhibit decreased protease activity in bone marrow-derived mast cells.

Authors:  Shiori Ohtake-Niimi; Sachiko Kondo; Tatsuro Ito; Saori Kakehi; Tadayuki Ohta; Hiroko Habuchi; Koji Kimata; Osami Habuchi
Journal:  J Biol Chem       Date:  2010-05-03       Impact factor: 5.157

Review 2.  Mast cell proteoglycans.

Authors:  Elin Rönnberg; Fabio R Melo; Gunnar Pejler
Journal:  J Histochem Cytochem       Date:  2012-08-16       Impact factor: 2.479

3.  Down-regulation of chondroitin 4-O-sulfotransferase-1 by Wnt signaling triggers diffusion of Wnt-3a.

Authors:  Satomi Nadanaka; Hiroki Kinouchi; Kayo Taniguchi-Morita; Jun-ichi Tamura; Hiroshi Kitagawa
Journal:  J Biol Chem       Date:  2010-12-01       Impact factor: 5.157

4.  Regulation of chondroitin-4-sulfotransferase (CHST11) expression by opposing effects of arylsulfatase B on BMP4 and Wnt9A.

Authors:  Sumit Bhattacharyya; Leo Feferman; Joanne K Tobacman
Journal:  Biochim Biophys Acta       Date:  2014-12-12

5.  Inhibition of N-acetylgalactosamine 4-sulfate 6-O-sulfotransferase by beta-D-4-O-sulfo-N-acetylgalactosaminides bearing various hydrophobic aglycons.

Authors:  Hiroko Nozaki; Yuri Tomoyama; Hideyuki Takagi; Koutaro Yokoyama; Chika Yamada; Ken-ichi Kaio; Masaki Tsukimori; Kazuya Nagao; Yuya Itakura; Shiori Ohtake-Niimi; Hirofumi Nakano; Osami Habuchi
Journal:  Glycoconj J       Date:  2009-12-18       Impact factor: 2.916

6.  Pivotal Role of Carbohydrate Sulfotransferase 15 in Fibrosis and Mucosal Healing in Mouse Colitis.

Authors:  Kenji Suzuki; Somasundaram Arumugam; Junji Yokoyama; Yusuke Kawauchi; Yutaka Honda; Hiroki Sato; Yutaka Aoyagi; Shuji Terai; Kazuichi Okazaki; Yasuo Suzuki; Shuji Mizumoto; Kazuyuki Sugahara; Raja Atreya; Markus F Neurath; Kenichi Watanabe; Taishi Hashiguchi; Hiroyuki Yoneyama; Hitoshi Asakura
Journal:  PLoS One       Date:  2016-07-13       Impact factor: 3.240

Review 7.  Mast cell glycosaminoglycans.

Authors:  B Mulloy; R Lever; C P Page
Journal:  Glycoconj J       Date:  2016-11-30       Impact factor: 2.916

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.